Copyright (c) 2007 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 Prous Science

FILE 'TOXCENTER' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 ACS

FILE 'USPATFULL' ENTERED AT 11:14:14 ON 12 FEB 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:14:14 ON 12 FEB 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 11:14:14 ON 12 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s shrew and paralytic peptide and fragment
  21 FILES SEARCHED...
  54 FILES SEARCHED...
L1   12 SHREW AND PARALYTIC PEPTIDE AND FRAGMENT

=> dup rem
ENTER L# LIST OR (END):L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR,
PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L1
L2   5 DUP REM L1 (7 DUPLICATES REMOVED)

=> d L2 1-5 ibib,abs

L2   ANSWER 1 OF 5 IFIPAT COPYRIGHT 2007 IFI on STN DUPLICATE 1
AN   11370247 IFIPAT;IFIUDB;IFICDB
TITLE: PARALYTIC PEPTIDE FOR USE IN
                        NEUROMUSCULAR THERAPY
INVENTOR(S):   Steeves; Bradley J., Riverview, CA
                        Stewart; John M., Sackville, CA
                        Vernes; Karl, Ferntree Gully, AU
PATENT ASSIGNEE(S):   Unassigned
AGENT: SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101
                        MARKET STREET, PHILADELPHIA, PA, 191072950, US

                           NUMBER   PK   DATE
                        ---------------- -- --------
PATENT INFORMATION: US 2007020251   A1 20070125
APPLICATION INFORMATION: US 2006-507128   20060821

                                                GRANTED PATENT NO.

	APPLN. NUMBER	DATE	OR STATUS
CONTINUATION OF:	US 2004-858233	20040601	7119168
CONTINUATION-IN-PART OF:	US 2003-716314	20031118	PENDING

	NUMBER	DATE	
PRIORITY APPLN. INFO.:	US 2002-427682P	20021118	(Provisional)
FAMILY INFORMATION:	US 2007020251	20070125	
	US 7119168		
DOCUMENT TYPE:	Utility		
	Patent Application - First Publication		
FILE SEGMENT:	CHEMICAL		
	APPLICATION		

PARENT CASE DATA:

This application is a continuation-in-part of U.S. application Ser. No. 10/716,314 filed on Nov. 18, 2003, which claims priority from U.S. application No. 60/427,682, filed Nov. 18, 2002, both of which are incorporated by reference herein in their entirety.

NUMBER OF CLAIMS: 15 17 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1. Amino acid sequences: A. (SEQ ID NO:1); B. (SEQ ID NO:2).
FIG. 2. Size exclusion chromatography of shrew submaxilary gland extract with bioactive fractions indicated by cross-hatching.
FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The small active component exists as part of a very high molecular weight complex.
FIG. 4. First HPLC elution profile of active fraction.
FIG. 5. Second HPLC elution profile of active fraction.
FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenate stained for glycoproteins.
FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva and submaxilary homogenate.
FIG. 8. Capillary electrophoretogram of the isolated and purified shrew saliva peptide in sodium borate buffer.
FIG. 9. Capillary electrophoretogram of the isolated and purified shrew saliva peptide.
FIG. 10. Ultra-violet spectrum of the isolated and purified shrew saliva peptide.
FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrew saliva peptide.
FIG. 12. Peptide mass mapping of tryptic peptides of the isolated and purified ***shrew*** saliva peptide.
FIG. 13. MASCOT searching results of the MS/MS data from HPLCESI-Q-TOF analysis.
FIG. 14. Mealworms immediately post-injection and with total paralysis.
FIG. 15. Migration time vs isoelectric pH of Beckman-Coulter pI standard proteins.
FIG. 16. The increased fluorescence due to calcium ion uptake by ovarian carcinoma cell line OV-2008 and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after initial treatment with calcium chloride (to a final concentration of 2.5 mM), potassium chloride (to 20 mM) and a final calcium chloride (to a final concentration of 5.0 mM) treatments.
FIG. 17. The increased fluorescence due to calcium ion uptake by insect nerve tissue and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after a challenge with calcium chloride (to a final concentration of 2.5 mM) and potassium chloride (to 20 mM).

AB The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel

paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.

CLMN 15 17 Figure(s).

FIG. 1. Amino acid sequences: A. (SEQ ID NO:1); B. (SEQ ID NO:2).

FIG. 2. Size exclusion chromatography of shrew submaxilary gland extract with bioactive fractions indicated by cross-hatching.

FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The small active component exists as part of a very high molecular weight complex.

FIG. 4. First HPLC elution profile of active fraction.

FIG. 5. Second HPLC elution profile of active fraction.

FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenate stained for glycoproteins.

FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva and submaxilary homogenate.

FIG. 8. Capillary electrophoretogram of the isolated and purified shrew saliva peptide in sodium borate buffer.

FIG. 9. Capillary electrophoretogram of the isolated and purified shrew saliva peptide.

FIG. 10. Ultra-violet spectrum of the isolated and purified shrew saliva peptide.

FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrew saliva peptide.

FIG. 12. Peptide mass mapping of tryptic peptides of the isolated and purified shrew saliva peptide.

FIG. 13. MASCOT searching results of the MS/MS data from HPLCESI-Q-TOF analysis.

FIG. 14. Mealworms immediately post-injection and with total paralysis.

FIG. 15. Migration time vs isoelectric pH of Beckman-Coulter pI standard proteins.

FIG. 16. The increased fluorescence due to calcium ion uptake by ovarian carcinoma cell line OV-2008 and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after initial treatment with calcium chloride (to a final concentration of 2.5 mM), potassium chloride (to 20 mM) and a final calcium chloride (to a final concentration of 5.0 mM) treatments.

FIG. 17. The increased fluorescence due to calcium ion uptake by insect nerve tissue and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after a challenge with calcium chloride (to a final concentration of 2.5 mM) and potassium chloride (to 20 mM).

L2 ANSWER 2 OF 5 IFIPAT COPYRIGHT 2007 IFI on STN DUPLICATE 2

AN	11268241 IFIPAT;IFIUDB;IFICDB		
TITLE:	PARALYTIC PEPTIDE FOR USE IN NEUROMUSCULAR THERAPY		
INVENTOR(S):	Steeves; Bradley J., Riverview, CA Stewart; John M., Sackville, CA Vernes; Karl, Ferntree Gully, AU		
PATENT ASSIGNEE(S):	Unassigned		
AGENT:	SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950, US		
	NUMBER	PK	DATE
PATENT INFORMATION:	US 2006217302	A1	20060928
APPLICATION INFORMATION:	US 2003-716314		20031118
	NUMBER		DATE
PRIORITY APPLN. INFO.:	US 2002-427682P		20021118 (Provisional)
FAMILY INFORMATION:	US 2006217302		20060928
DOCUMENT TYPE:	Utility Patent Application - First Publication		

FILE SEGMENT: CHEMICAL
APPLICATION

PARENT CASE DATA:

This application claims priority from U.S. application No. 60/ 427,682, filed Nov. 18, 2002, which is incorporated by reference herein in its entirety.

NUMBER OF CLAIMS: 28 14 Figure(s).
DESCRIPTION OF FIGURES:
FIG. 1. Amino acid sequences of isolated and purified shrew saliva protein: A. (SEQ ID NO:1); B. (SEQ ID NO:2)
FIG. 2. Size exclusion chromatography of shrew submaxilary gland extract with bioactive fractions indicated by cross-hatching.
FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The small active component exists as part of a very high molecular weight complex.
FIG. 4. First HPLC elution profile of active fraction.
FIG. 5. Second HPLC elution profile of active fraction.
FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenate stained for glycoproteins.
FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva and submaxilary homogenate.
FIG. 8. Capillary electrophoretogram of the isolated and purified shrew saliva peptide in sodium borate buffer.
FIG. 9. Capillary electrophoretogram of the isolated and purified shrew saliva peptide.
FIG. 10. Ultra-violet spectrum of the isolated and purified shrew saliva peptide.
FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrew saliva peptide.
FIG. 12. Peptide mass mapping of tryptic peptides of the isolated and purified ***shrew*** saliva peptide.
FIG. 13. MASCOT searching results of the MS/MS data from HPLCESI-Q-TOF analysis.
FIG. 14. Mealworms immediately post-injection and with total paralysis.
AB The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic.
CLMN 28 14 Figure(s).
FIG. 1. Amino acid sequences of isolated and purified shrew saliva protein: A. (SEQ ID NO:1); B. (SEQ ID NO:2)
FIG. 2. Size exclusion chromatography of shrew submaxilary gland extract with bioactive fractions indicated by cross-hatching.
FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The small active component exists as part of a very high molecular weight complex.
FIG. 4. First HPLC elution profile of active fraction.
FIG. 5. Second HPLC elution profile of active fraction.
FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenate stained for glycoproteins.
FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva and submaxilary homogenate.
FIG. 8. Capillary electrophoretogram of the isolated and purified shrew saliva peptide in sodium borate buffer.
FIG. 9. Capillary electrophoretogram of the isolated and purified shrew saliva peptide.
FIG. 10. Ultra-violet spectrum of the isolated and purified shrew saliva peptide.
FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrew saliva peptide.
FIG. 12. Peptide mass mapping of tryptic peptides of the isolated and purified shrew saliva peptide.
FIG. 13. MASCOT searching results of the MS/MS data from HPLCESI-Q-TOF

analysis.
FIG. 14. Mealworms immediately post-injection and with total paralysis.

L2 ANSWER 3 OF 5 IFIPAT COPYRIGHT 2007 IFI on STN

AN	04492702 IFIPAT;IFIUDB;IFICDB
TITLE:	PARALYTIC PEPTIDE FOR USE IN NEUROMUSCULAR THERAPY; ISOLATED FROM THE SUBMAXILIARY SALIVA GLANDS OF SHREWS; CALCIUM CHANNEL BLOCKER, ANALGESIC, INSECTICIDE
INVENTOR(S):	Steeves; Bradley J., Riverview, CA Stewart; John M., Sackville, CA Vernes; Karl, Ferntree Gully, AU
PATENT ASSIGNEE(S):	BioProspecting NB Inc., Sackville, CA
PRIMARY EXAMINER:	Carlson, Karen Cochrane
ASSISTANT EXAMINER:	Rooke, Agnes B
AGENT:	Synnestvedt & Lechner LLP

	NUMBER	PK	DATE
PATENT INFORMATION:	US 7119168	B2	20061010
	US 2005181992	A1	20050818
APPLICATION INFORMATION:	US 2004-858233		20040601
EXPIRATION DATE:	18 Nov 2023		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION-IN-PART OF:	US 2003-716314	20031118	PENDING

	NUMBER	DATE	
PRIORITY APPLN. INFO.:	US 2002-427682P	20021118	(Provisional)
FAMILY INFORMATION:	US 7119168	20061010	

DOCUMENT TYPE:	Utility Granted Patent - Utility, with Pre-Grant Publication
FILE SEGMENT:	CHEMICAL GRANTED

PARENT CASE DATA:

This application is a continuation-in-part of U.S. application Ser. No. 10/716,314 filed on Nov. 18, 2003, which claims priority from U.S. application No. 60/427,682, filed Nov. 18, 2002, both of which are incorporated by reference herein in their entirety.

NUMBER OF CLAIMS:	20
GRAPHICS INFORMATION:	13 Drawing Sheet(s), 15 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1. Amino acid sequences: A. (SEQ ID NO:1); B. (SEQ ID NO:2).
FIG. 2. Size exclusion chromatography of shrew submaxilary gland extract with bioactive fractions indicated by cross-hatching.
FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The small active component exists as part of a very high molecular weight complex.
FIG. 4. First HPLC elution profile of active fraction.
FIG. 5. Second HPLC elution profile of active fraction.
FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenate stained for glycoproteins.
FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva and submaxilary homogenate.
FIG. 8. Capillary electrophoretogram of the isolated and purified shrew saliva peptide in sodium borate buffer.
FIG. 9. Capillary electrophoretogram of the isolated and purified shrew saliva peptide.
FIG. 10. Ultra-violet spectrum of the isolated and purified shrew

saliva peptide.
FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrew saliva peptide.
FIG. 12. Peptide mass mapping of tryptic peptides of the isolated and purified ***shrew*** saliva peptide.
FIG. 13. MASCOT searching results of the MS/MS data from HPLCESI-Q-TOF analysis.
FIG. 14. Mealworms immediately post-injection and with total paralysis.
FIG. 15. Migration time vs isoelectric pH of Beckman-Coulter pI standard proteins.
FIG. 16. The increased fluorescence due to calcium ion uptake by ovarian carcinoma cell line OV-2008 and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after initial treatment with calcium chloride (to a final concentration of 2.5 mM), potassium chloride (to 20 mM) and a final calcium chloride (to a final concentration of 5.0 mM) treatments.
FIG. 17. The increased fluorescence due to calcium ion uptake by insect nerve tissue and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after a challenge with calcium chloride (to a final concentration of 2.5 mM) and potassium chloride (to 20 mM).

AB The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.

CLMN 20

GI 13 Drawing Sheet(s), 15 Figure(s).

FIG. 1. Amino acid sequences: A. (SEQ ID NO:1); B. (SEQ ID NO:2).
FIG. 2. Size exclusion chromatography of shrew submaxilary gland extract with bioactive fractions indicated by cross-hatching.
FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The small active component exists as part of a very high molecular weight complex.
FIG. 4. First HPLC elution profile of active fraction.
FIG. 5. Second HPLC elution profile of active fraction.
FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenate stained for glycoproteins.
FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva and submaxilary homogenate.
FIG. 8. Capillary electrophoretogram of the isolated and purified shrew saliva peptide in sodium borate buffer.
FIG. 9. Capillary electrophoretogram of the isolated and purified shrew saliva peptide.
FIG. 10. Ultra-violet spectrum of the isolated and purified shrew saliva peptide.
FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrew saliva peptide.
FIG. 12. Peptide mass mapping of tryptic peptides of the isolated and purified shrew saliva peptide.
FIG. 13. MASCOT searching results of the MS/MS data from HPLCESI-Q-TOF analysis.
FIG. 14. Mealworms immediately post-injection and with total paralysis.
FIG. 15. Migration time vs isoelectric pH of Beckman-Coulter pI standard proteins.
FIG. 16. The increased fluorescence due to calcium ion uptake by ovarian carcinoma cell line OV-2008 and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin after initial treatment with calcium chloride (to a final concentration of 2.5 mM), potassium chloride (to 20 mM) and a final calcium chloride (to a final concentration of 5.0 mM) treatments.
FIG. 17. The increased fluorescence due to calcium ion uptake by insect nerve tissue and subsequent formation of the FURA/Ca+2 in the absence (control) and presence of the paralytic shrew peptide soricidin

after a challenge with calcium chloride (to a final concentration of 2.5 mM) and potassium chloride (to 20 mM).

L2 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:823304 CAPLUS
DOCUMENT NUMBER: 143:224069
TITLE: Paralytic peptide from shrew saliva, named PS peptide or soricidin, for use as neuromuscular blocker, analgesic, cosmetic or as an insecticide
INVENTOR(S): Stewart, John M.; Steeves, Bradley J.; Vernes, Karl
PATENT ASSIGNEE(S): Bioprospecting Nb Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 716,314.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005181992	A1	20050818	US 2004-858233		20040601
US 7119168	B2	20061010			
US 2006217302	A1	20060928	US 2003-716314		20031118
US 2007020251	A1	20070125	US 2006-507128		20060821
PRIORITY APPLN. INFO.:			US 2002-427682P	P	20021118
			US 2003-716314	A2	20031118
			US 2004-858233	A1	20040601

AB The invention involves isolation and purification of a low mol. weight peptide paralytic agent from shrew (Bravina brevicada) submaxillary salivary gland or saliva (called "PS peptide" or soricidin). The peptide preferably has 54 amino acids (Seq ID NO: 1), and a mol. weight of about 6000 Da as measured by SDS-PAGE. The peptide may be isolated from any shrew having paralytic activity in its saliva, such as Blarina, Neomys and Sorex shrew species. The invention also optionally includes a toxicity bioassay using the common meal-worm or other insect for rapid assessment of paralytic bioactivity. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 5 BIOTECHDS COPYRIGHT 2007 THE THOMSON CORP. on STN DUPLICATE 4
ACCESSION NUMBER: 2004-15853 BIOTECHDS
TITLE: New shrew paralytic peptide isolated from the submaxillary glands of the Blarina shrew, useful as a neuromuscular blocker, or as an analgesic, and for treating migraine, muscle tremors, excessive sweating and wrinkles;
involving vector-mediated gene transfer and expresion in host cell
AUTHOR: STEWART J M; STEEVES B J; VERNES K
PATENT ASSIGNEE: STEWART J M; STEEVES B J; VERNES K
PATENT INFO: WO 2004046178 3 Jun 2004
APPLICATION INFO: WO 2003-CA1749 18 Nov 2003
PRIORITY INFO: US 2002-427682 18 Nov 2002; US 2002-427682 18 Nov 2002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2004-431942 [40]
AN 2004-15853 BIOTECHDS
AB DERWENT ABSTRACT:
NOVELTY - A new isolated shrew paralytic peptide (I): (a) having a molecular weight of 6000 Da as measured

by SDS-PAGE and a fully defined sequence of 54 amino acids (SEQ ID NO: 1 or 2) given in the specification; or (b) comprising a fragment of 5-10, 10-15, 15-20, or 20-24 amino acids of (a).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a pharmaceutical composition or cosmetic composition including (I); (2) an isolated and purified multiprotein complex comprising (I) and having a molecular weight of greater than or equal to 600000 daltons;(3) dissociating (I) from the multiprotein complex of (2), comprising contacting the multiprotein complex with sodium docecylsulfate or aqueous alcohol or warming at 40degreesC; (4) an antibody to (I); (5) determining the potency of a paralytic agent, comprising administering the paralytic agent to a mealworm or other insect, determining the time until onset of paralysis and/or the duration of paralysis, where the time for onset of paralysis is inversely proportional to the strength of the paralytic agent and the duration of paralysis is proportional to the strength of the paralytic agent; and (6) a nucleic acid encoding (I).

BIOTECHNOLOGY - Preferred Peptide: (I) includes at least one cysteine amino acid having a sulfhydryl group, and further comprises at least 2 or 6 cysteine amino acids each having a sulfhydryl group and forming a disulfhydryl bond. (I) further has the property of absorbing light at 280 nm and stronger at 260 nm, and including at least one aromatic amino acid. (I) is isolated from a shrew submaxillary gland and/or shrew saliva, where the shrew submaxillary gland is isolated from Blarina brevicauda, Blarina carolinensis, Sorex unguiculatus, Sorex shinto saevu (Solenodon paradoxus), Neomys fodiens or Neomys anomalous. A 10 microliter dose of 20% (w/v) crude gland extract injected into a mealworm in an in vitro assay causes mealworm paralysis in less than 1 second, and a 10 microliter dose of 10% (w/v) crude gland extract injected into a mealworm in an in vitro assay causes mealworm paralysis in less than 10 seconds. (I) is in a purified form, and is purified at least 90%, 95% or 99%.

ACTIVITY - Analgesia; Antimigraine; Anticonvulsant; Dermatological; Vulnerary. No biological data given.

MECHANISM OF ACTION - Neuromuscular Blocker.

USE - The isolated shrew paralytic peptide is useful as a pharmaceutical substance, neuromuscular blocker, or as an insect immobilizing agent. The peptide and compositions comprising the peptide are useful for treating migraine, myofacial and other types of pain, muscle tremors, neuromuscular diseases, excessive sweating; as analgesic for wounds; for reducing wrinkles; or as neuromuscular blocker (all claimed).

ADMINISTRATION - Routes of administration of the pharmaceutical compositions include oral, topical, aerosol, intramuscular, intraperitoneal, intravenous, subcutaneous, inhalation and intratracheal. No dosage given.

EXAMPLE - Experimental protocols are described but no results given. (47 pages)

=> d his

(FILE 'HOME' ENTERED AT 11:12:05 ON 12 FEB 2007)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, FOMAD, ...' ENTERED AT 11:14:14 ON 12 FEB 2007

L1 12 S SHREW AND PARALYTIC PEPTIDE AND FRAGMENT
L2 5 DUP REM L1 (7 DUPLICATES REMOVED)

=>
Connection closed by remote host

Refine Search

Search Results -

Term	Documents
PEPTIDE	211016
PEPTIDES	153914
(2 AND PEPTIDE).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	7
(L2 AND PEPTIDE).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	7

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L3 and fragment

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Monday, February 12, 2007 Purge Queries Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L3	L2 and peptide	7	L3
L2	L1 and paralytic	7	L2
L1	shrew	216	L1

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 20070020251 A1

L3: Entry 1 of 7 File: PGPB Jan 25, 2007

PGPUB-DOCUMENT-NUMBER: 20070020251
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20070020251 A1

TITLE: Paralytic peptide for use in neuromuscular therapy

PUBLICATION-DATE: January 25, 2007

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Stewart; John M.	Sackville		CA
Steeves; Bradley J.	Riverview		CA
Vernes; Karl	Ferntree Gully		AU

US-CL-CURRENT: 424/94.1; 435/320.1, 435/325, 435/69.1, 530/324, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20060217302 A1

L3: Entry 2 of 7 File: PGPB Sep 28, 2006

PGPUB-DOCUMENT-NUMBER: 20060217302
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060217302 A1

TITLE: Paralytic peptide for use in neuromuscular therapy

PUBLICATION-DATE: September 28, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Stewart; John M.	Sackville		CA
Steeves; Bradley J.	Riverview		CA
Vernes; Karl	Ferntree Gully		AU

US-CL-CURRENT: 514/12; 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20050181992 A1

L3: Entry 3 of 7 File: PGPB Aug 18, 2005

PGPUB-DOCUMENT-NUMBER: 20050181992
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050181992 A1

TITLE: Paralytic peptide for use in neuromuscular therapy

PUBLICATION-DATE: August 18, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Stewart, John M.	Sackville		CA
Steeves, Bradley J.	Riverview		CA
Vernes, Karl	Ferntree Gully		AU

US-CL-CURRENT: 514/12; 530/324

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 7119168 B2

L3: Entry 4 of 7 File: USPT Oct 10, 2006

US-PAT-NO: 7119168
DOCUMENT-IDENTIFIER: US 7119168 B2

TITLE: Paralytic peptide for use in neuromuscular therapy

DATE-ISSUED: October 10, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20050181992 A1	August 18, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stewart; John M.	Sackville			CA
Steeves; Bradley J.	Riverview			CA
Vernes; Karl	Ferntree Gully			AU

US-CL-CURRENT: 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | | Claims | KWIC | Draw D

5. Document ID: EP 1601691 A2

L3: Entry 5 of 7 File: EPAB Dec 7, 2005

PUB-NO: EP001601691A2
DOCUMENT-IDENTIFIER: EP 1601691 A2
TITLE: SHREW PARALYTIC PEPTIDE FOR USE IN NEUROMUSCULAR THERAPY

PUBN-DATE: December 7, 2005

INVENTOR-INFORMATION:

NAME	COUNTRY
STEWART, JOHN M	CA
STEEVES, BRADLEY J	CA
VERNES, KARL	AU

INT-CL (IPC): C07K 14/47; A61K 38/17
EUR-CL (EPC): C07K014/47

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D

6. Document ID: WO 2004046178 A2

L3: Entry 6 of 7 File: EPAB Jun 3, 2004

PUB-NO: WO2004046178A2
DOCUMENT-IDENTIFIER: WO 2004046178 A2
TITLE: PARALYTIC PEPTIDE FOR USE IN NEUROMUSCULAR THERAPY

PUBN-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
STEWART, JOHN M	CA
STEEVES, BRADLEY J	CA
VERNES, KARL	AU

INT-CL (IPC): C07K 14/435
EUR-CL (EPC): C07K014/47

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw D

7. Document ID: US 20070020251 A1, WO 2004046178 A2, AU 2003283160 A1, US 20050181992 A1, EP 1601691 A2, AU 2003283160 A8, US 20060217302 A1, US 7119168 B2

L3: Entry 7 of 7 File: DWPI Jan 25, 2007

DERWENT-ACC-NO: 2004-431942
DERWENT-WEEK: 200710

TITLE: New shrew paralytic peptide isolated from the submaxillary glands of the Blarina shrew, useful as a neuromuscular blocker, or as an analgesic, and for treating migraine, muscle tremors, excessive sweating and wrinkles

INVENTOR: STEEVES, B J; STEWART, J M ; VERNES, K

PRIORITY-DATA: 2002US-427682P (November 18, 2002), 2003US-0716314 (November 18, 2003), 2004US-0858233 (June 1, 2004), 2006US-0507128 (August 21, 2006)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20070020251 A1	January 25, 2007		000	A61K038/43
WO 2004046178 A2	June 3, 2004	E	047	C07K014/435
AU 2003283160 A1	June 15, 2004		000	C07K014/435
US 20050181992 A1	August 18, 2005		000	A61K038/17
EP 1601691 A2	December 7, 2005	E	000	C07K014/47
AU 2003283160 A8	November 3, 2005		000	C07K014/47
US 20060217302 A1	September 28, 2006		000	A61K038/17
US 7119168 B2	October 10, 2006		000	C07K001/00

INT-CL (IPC): A61K 38/17; A61K 38/43; C07H 21/00; C07H 21/04; C07K 1/00; C07K 14/00; C07K 14/435; C07K 14/47; C07K 17/00; C12P 21/06

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents
PEPTIDE	211016
PEPTIDES	153914
(2 AND PEPTIDE).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	7
(L2 AND PEPTIDE).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	7

Display Format: - Change Format

Previous Page Next Page Go to Doc#